On a Tuesday morning in a suburban medical park, a fertility clinic changed its name. The doctors were the same. The embryologists were the same. The waiting room chairs were the same. Only the sign, the billing system, and the website changed — the clinic was now part of a network, one of dozens acquired in the past few years by private-equity-backed groups that have quietly become the largest force in American fertility care.
The roll-up of fertility medicine is one of the least-noticed consolidations in healthcare, and it will shape what families pay, where they can get care, and how much choice they have. Understanding it is essential to understanding the price of a baby in America.
A fragmented field, suddenly in play
Fertility care was, for decades, a cottage industry. Most clinics were founded by one or two reproductive endocrinologists, served a single city, and grew by reputation. The American Society for Reproductive Medicine counts more than 450 reporting fertility clinics in the United States, and the CDC's annual assisted reproduction reports list hundreds of distinct programs. That fragmentation made the field a natural target for consolidation: many small, profitable practices, no dominant national brand, and demand that rises with delayed parenthood.
Private equity arrived in force in the late 2010s. US Fertility, formed from the merger of Shady Grove Fertility and several regional practices, became the largest network in the country, backed by the investment firm Amulet Capital. Prelude Fertility, backed by Lee Equity Partners, assembled clinics under brands including Inception Fertility and The Prelude Network. IVI RMA, the American arm of the Spanish group IVI, expanded through acquisitions across the United States. Kindbody, founded in 2018, took a different route — building new clinics and raising venture capital, including a large round led by Perceptive Advisors — but with the same goal: scale.
The logic of scale is straightforward: better drug and equipment prices, centralized embryology expertise, standardized protocols, national marketing — and, crucially, the ability to sell a single employer contract covering twenty cities.
What scale does to price
The evidence on price is mixed, and that mix is the story. On one hand, networks have introduced published pricing, refund programs, and multi-cycle packages that independent clinics rarely offered. Shady Grove's shared-risk program, under which patients pay a higher upfront fee in exchange for a partial refund if treatment does not result in a live birth, is a product only a large network can credibly offer — it depends on pooling risk across thousands of patients. Kindbody's published prices and employer deals similarly reflect a scale business model: standardize the offering, state the price, sell at volume.
On the other hand, consolidation in healthcare has a well-documented tendency to raise prices once a market concentrates. Studies of hospital mergers by researchers at the University of California, Berkeley, and others have repeatedly found that mergers in already-concentrated markets lead to higher prices, not lower ones. Fertility is not hospital care, and the analogy is imperfect — patients can travel, and many pay out of pocket, which sharpens price sensitivity. Still, the direction of travel deserves attention: when three networks control most clinics in a metro area, the competitive pressure that once disciplined prices weakens.
Fertility price data is thinner than it should be — itself a symptom. Because most clinics do not publish all-in prices, researchers cannot easily track whether network-owned clinics charge more than independents in the same city. Patient surveys from FertilityIQ show wide variation even within single cities, with total spending of $30,000 or more common across cycles. In a market this opaque, consolidation can proceed without price effects being visible until they are entrenched.
Quality, access, and the small clinic
Consolidation's defenders point to quality: a network can invest in time-lapse embryo imaging, advanced genetic testing, and AI embryo assessment that a small clinic cannot afford alone, move embryologists between sites, and maintain standards across locations. CDC data show larger, high-volume programs often report strong live-birth rates, though volume alone does not guarantee success for any individual patient.
The risk is access outside the networks' footprint. Independent clinics in smaller cities and lower-income neighborhoods are least likely to be acquired and most likely to struggle as networks concentrate marketing and employer contracts in major metros. CDC data already show stark unevenness: California, New York, Texas, and Florida account for a disproportionate share of cycles, while many states have only a handful of clinics.
Clinical independence also narrows: protocols, formularies, and laboratory choices increasingly come from the network, which can improve consistency but limit individualized approaches for complex cases such as diminished ovarian reserve or recurrent pregnancy loss.
The counterargument, stated fairly
It would be wrong to cast consolidation as a simple story of corporate extraction. Many independent clinics wanted to sell. Founders approaching retirement had no succession plan; younger physicians preferred employment to the financial risk of owning a practice; and the capital demands of modern embryology — new incubators, genetic testing platforms, electronic records — favored larger organizations. Private equity did not invent those pressures. It answered them.
Patients, too, have benefited: extended hours, satellite offices, telehealth monitoring, and — for patients who move mid-treatment — a network clinic in the new city that can continue a protocol without starting over. Those are genuine gains.
The fair test is not whether consolidation has any benefits. It does. The test is whether its benefits are shared with patients in the form of lower all-in prices and better outcomes, or captured by investors in the form of higher margins. That test cannot be passed in press releases. It requires data: published prices, published outcomes by age band, and independent comparison. The networks that publish both will earn trust. The ones that publish neither should be asked why.
The implications
Three developments will determine how this story ends. First, employer and insurer purchasing power. As fertility benefits expand, the buyers with the most leverage — large employers, benefits managers like Progyny and Carrot, and state Medicaid programs in the few states that cover fertility care — will demand price and outcome data as a condition of contracting. That demand is already reshaping clinic behavior, and it will intensify.
Second, regulation. The Federal Trade Commission has scrutinized healthcare roll-ups, and state attorneys general have challenged physician-practice acquisitions that reduce local competition. Fertility has drawn less antitrust attention than hospitals so far, but that may change as networks grow.
Third, patient information. The single most powerful check on consolidation is a patient who can compare clinics on price and outcomes before choosing. That requires standardized reporting — the CDC already collects cycle and outcome data, but it is published with a lag and without prices. Pairing outcome reporting with price reporting, by clinic and by age band, would give families the tool they need and give researchers the data to test whether consolidation helps or hurts.
Back in that suburban medical park, the clinic with the new sign still treats the same patients, with the same doctors, in the same rooms. The change that matters is not on the wall: it is who owns the practice, who sets the price, and what a patient is told before she commits. Families cannot control clinic ownership. They can control the questions they ask: What is the all-in price? What is your live-birth rate for patients my age? What happens if this cycle fails? In a consolidating market, those questions are the last, best defense of choice.
Sources: Sources cited in this article: American Society for Reproductive Medicine clinic counts; CDC Assisted Reproductive Technology annual reports; company materials from US Fertility, Shady Grove Fertility, Prelude Fertility, Inception Fertility, IVI RMA, Kindbody, Progyny, and Carrot Fertility; University of California, Berkeley hospital-merger price research; FertilityIQ patient cost surveys.